Member Info for JSB1989

Dallo,

I have been keenly tracking Vor and it has done remarkable in such a short time frame. The 2% of ours is only worth $6 million currently so I’d keep that investment.

The pivotal moment will be what’s happening with LYT-100. Respiratory drugs are becoming hot property so will be interesting to see if big pharma want it pre P3 or maybe JV in to support funding.

If anyone remembers Verona Pharma which was listed in London. It has been bought for $10 billion by Merck at around $107 per share. It delisted in late 2020 from London and was trading at $5-6 so that’s a 20 bag for holders.

Highlights the opportunity for Puretech, but also some proactive management. Delist off London and move to the Nasdaq. Rerate will begin.

Chairman out and the share price is up. Who is next for the boot? So much value to unlock with the correct team.

Yes they have at least declared under the 0.5% threshold. I doubt they have closed it all given the low volumes in the last two weeks but you would expect they will continue to close this.

Q3 and Q4 is where the company is expected to be busy.

I don’t understand the UK primary listing. The ADR is very illiquid and the UK volume is abysmal. Once the funding for LYT-100 has been established, they should make the move.

Great comments and assessments today.

I don’t know about everybody else but I am often put off by shares that have a notified short interest. Maybe the 1.3% short could be acting to keep retail disinterested, volumes dry up and it could help to orchestrate a lowball takeover. I’d love to know what Nordic initially offered.

Q3 is where BC said that LYT-100 news is due for update and that starts on Tuesday. Certainly is a testing share especially when you see garbage like treasury stocks flying to the moon.

That’s 1% in one week. The end game has to come soon enough right?

You’ve got EIT buying by the fistful every day. They see the future in genomics. It will scale up and be utilised widely as the technology progresses. Shorting it would be grave and costly.

The initial data was released in December and after an initial uptick, the share price receded. The lung function data was exceptional, but I get the sense that analysts expected slightly better from the safety. Phase 3 funding is the key to unlocking any value in LYT-100 now. If they only need to commit $50-100 million to the P3, that would be a great result and leave plenty of runway for other assets.

I don’t want Puretech to take LYT-100 alone as I’ve held binary biotechs and that’s very stressful and risky.

On the flip side, if LYT-100 was shelved due to a lack of funding, it wouldn’t crater the share price. You’d still have $300 million in cash, 35% in Vedanta and Seaport, 100% Gallop (which will reduce once it has spun off) and Cobenfy payments. The NAV of that is significantly above today’s SP.

The problem here is management. Delist from London, and take the listing solely to the Nasdaq. They’ve nothing to lose.

That will help cubed. Hopefully we are in an uptrend leading into results in July.

Nice uptick for Vor. The last time I checked in May, they were looking to wind down the company and the share price had crashed to 0.15, now 10x of that. It’s still peanuts for PRTC given it had 2% before this fundraise. It does go to show, how quickly biotech can turn around with the right news.

Golfnut - surely that can’t be the case. The cash runway is 3 years at least. With LYT-100 funding and a Gallop spinout in the coming months, this will leave Puretech with salaries(too high) and a much reduced R&D expenditure.

The shorters will know alongside us that the management is both passive and defensive. They aren’t proactively looking for new assets in the market or attempting buybacks. The sector for the minnows is still in the doldrums.

It’s ridiculous. Feels like dead money sat here but that’s often where the explosive moves in share price come from.

The increase in short baffles me. I don’t understand the case for doing it. Are they assuming the money runs out before any major catalyst?

The shorts have slightly increased which is probably the reason for the drop from 140 to 125. They are trying to pull this back.

No doubt that this will be done using Nanopore. EIT are buying for a reason. There is a big Blair connection with this.

The 25million UT is a triple witching trade. The 2x2 million and 4 million are big after hours trades.

EIT must be within striking distance of launching a takeover or another diagnostic giant making a bid themselves. Either way, I see Nanopore doubling in the next few months.

Delphi Asset Management Corporation. They have 3% I believe.

It’s pretty apparent that EIT are wanting to either take ONT out or defend against anyone else taking it out. 15% bought in the open market in 10 months is aggressive buying and adding decent chunks daily.

Down over 10% in three days and now back to the shorters initial entry price back in April. Hopefully they take this chance to buyback at breakeven or slight profit. It has been walked down on tiny volume.

Hopefully BC and Co have news on financing for LYT-100 and the Gallop spinout is close!

Puretech should ditch London and list solely on the Nasdaq. Indivior have recently announced this. Biotech is dead on the London market. The only interest is in AZ and GSK.

The volumes of trading are miserably low and we are heading into summer which is quiet.